Link to the CDPHE 9-26-22 update
FDA authorized two updated bivalent booster products for the COVID-19 vaccine on August 31, 2022, and CDC approved the vaccines on September 1, 2022.
People aged 18 years and older are recommended to receive either the bivalent Moderna COVID-19 vaccine OR the bivalent Pfizer-BioNTech COVID-19 vaccine at least two months after the last dose in their primary series or last booster.
Monovalent Moderna and Pfizer-BioNTech vaccines should continue to be used for the primary vaccine series in all eligible individuals, including in those who will be eligible for a bivalent booster after completion of their primary series. Bivalent vaccines are not authorized for use as a primary series vaccine.
Monovalent mRNA COVID-19 vaccines are no longer authorized as booster doses for people aged 12 years and older. Any monovalent mRNA COVID-19 vaccine booster administered to people aged ≥12 years after FDA’s authorization of bivalent boosters (August 31, 2022) must be reported as a vaccine administration error to VAERS.
People are considered up to date with their COVID-19 vaccines if they have completed a COVID-19 vaccine primary series and received the most recent booster dose recommended for them by CDC.
Coadministration of COVID-19 booster vaccines with the annual influenza vaccine is encouraged for eligible patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.